- For Print
- April 24, 2024
亚洲彩票官网., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “亚洲彩票官网”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in the third quarter of fiscal year 2023 (October 1, 2023 – December 31, 2023).
This information is being disclosed in conjunction with today's announcement of the first quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). 亚洲彩票官网’s financial results for the fiscal year ended March 31, 2024, including details of LEQEMBI’s revenue, will be disclosed in 亚洲彩票官网's financial disclosure scheduled on May 15, 2024.
亚洲彩票官网 serves as the lead of lecanemab development and regulatory submissions globally with both 亚洲彩票官网 and Biogen Inc. co-commercializing and co-promoting the product and 亚洲彩票官网 having final decision-making authority.
&苍产蝉辫;銆赌
&苍产蝉辫;銆赌
Media Inquiries:
Public Relations Department,
亚洲彩票官网., Ltd.
+81-(0)3-3817-5120
&苍产蝉辫;銆赌銆�